Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  BJU International

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.13963PMID 28710901PMCID PMC6126916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

  2017cited by this paper
• Active surveillance for prostate cancer: current evidence and contemporary state of practice

  2016cited by this paper
• Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer

  2016cited by this paper
• Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable‐risk prostate cancer undergoing active surveillance

  2016cited by this paper
• Active surveillance for prostate cancer: a narrative review of clinical guidelines

  2016cited by this paper
• Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review.

  2015cited by this paper
• Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study

  2013cited by this paper
• Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer.

  2013cited by this paper
• Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men.

  2013cited by this paper
• Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

  2013cited by this paper
• Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

  2012cited by this paper
• Caveolin-1 Upregulation Contributes to c-Myc–Induced High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer

  2011cited by this paper
• Caveolin-1 as a potential high-risk prostate cancer biomarker.

  2011cited by this paper
• The role of caveolin-1 in prostate cancer: clinical implications

  2010cited by this paper
• Radical prostatectomy findings in patients predicted to have low‐volume/low‐grade prostate cancer diagnosed by extended‐core biopsies: an analysis of volume and zonal distribution of tumour foci

  2009cited by this paper
• Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

  2009cited by this paper
• Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

  2008cited by this paper
• How much does Gleason grade of follow‐up biopsy differ from that of initial biopsy in untreated, Gleason score 4–7, clinically localized prostate cancer?

  2007cited by this paper
• Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort

  2006cited by this paper
• The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

  2005cited by this paper
• The Youden Index and the Optimal Cut‐Point Corrected for Measurement Error

  2005cited by this paper
• Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.

  2003cited by this paper
• A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.

  2000cited by this paper
• Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells

  1998cited by this paper
• The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age.

  1992cited by this paper
• Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate

  1990cited by this paper
• Patterns of progression in prostate cancer.

  1986cited by this paper
• QUERY: GLASGOW INFIRMARY?

  1828cited by this paper

• Caveolin-1 in prostate Cancer: Novel insights and therapeutic opportunities-A review.

  2025cites this paper
• Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

  2023cites this paper
• Active Surveillance in Prostate Cancer: Current and Potentially Emerging Biomarkers for Patient Selection Criteria

  2022cites this paper
• Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review

  2021cites this paper
• Prostate Corpuscles: Looking for Biomarkers of Early Prostate Cancer

  2021cites this paper
• Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

  2020cites this paper
• Expression of Caveolin-1 Is Associated With Thyroid Function in Patients With Human Papillary Thyroid Carcinoma

  2020cites this paper
• Caveola-forming proteins and prostate cancer

  2020cites this paper
• Prostate Cancer Biomarkers

  2019cites this paper
• EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).

  2019cites this paper
• Research status and progress of the RNA or protein biomarkers for prostate cancer

  2019cites this paper
• Prostasomas: búsqueda de biomarcadores para la detección temprana del cáncer prostático

  2019cites this paper
• Research status and progress of the RNA or protein biomarkers for prostate cancer

  2019cites this paper
• Research status and progress of the RNA or protein biomarkers for prostate cancer

  2019cites this paper
• Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned

  2018cites this paper
• Caveolin-1-Knockout Mouse as a Model of Inflammatory Diseases

  2018cites this paper